BACKGROUND: The effects of the prokinetic drug mosapride on esophageal motor activity vary at standard doses. In addition to esophageal motor activities, compliance of the esophagogastric junction (EGJ) is important for prevention of gastroesophageal reflux. However, the effects of mosapride on EGJ compliance have not been reported. Here, we investigated the effects of high-dose mosapride on esophageal motor activities and EGJ compliance. METHODS: Nine healthy volunteers were enrolled in the study. Peristaltic esophageal contraction and lower esophageal sphincter pressures before and after administration of 40 mg mosapride were examined by high resolution esophageal manometry. Esophageal compliance was also investigated by intra-esophageal impedance planimetry (EndoFLIP(®)). RESULTS: High-dose mosapride augmented peristaltic contractions, especially in the distal esophageal segments (P < 0.05). The mean resting lower esophageal sphincter pressure was elevated from 25.0 mmHg before administration to 28.9 mmHg after (P < 0.05). In addition, mosapride significantly reduced EGJ compliance (P < 0.05). CONCLUSIONS: Mosapride at 40 mg augmented esophageal motor activities and reduced EGJ compliance in healthy volunteers.
BACKGROUND: The effects of the prokinetic drug mosapride on esophageal motor activity vary at standard doses. In addition to esophageal motor activities, compliance of the esophagogastric junction (EGJ) is important for prevention of gastroesophageal reflux. However, the effects of mosapride on EGJ compliance have not been reported. Here, we investigated the effects of high-dose mosapride on esophageal motor activities and EGJ compliance. METHODS: Nine healthy volunteers were enrolled in the study. Peristaltic esophageal contraction and lower esophageal sphincter pressures before and after administration of 40 mg mosapride were examined by high resolution esophageal manometry. Esophageal compliance was also investigated by intra-esophageal impedance planimetry (EndoFLIP(®)). RESULTS: High-dose mosapride augmented peristaltic contractions, especially in the distal esophageal segments (P < 0.05). The mean resting lower esophageal sphincter pressure was elevated from 25.0 mmHg before administration to 28.9 mmHg after (P < 0.05). In addition, mosapride significantly reduced EGJ compliance (P < 0.05). CONCLUSIONS:Mosapride at 40 mg augmented esophageal motor activities and reduced EGJ compliance in healthy volunteers.
Authors: H Miwa; K Inoue; K Ashida; T Kogawa; A Nagahara; S Yoshida; N Tano; Y Yamazaki; T Wada; D Asaoka; T Fujita; J Tanaka; T Shimatani; N Manabe; T Oshima; K Haruma; T Azuma; T Yokoyama Journal: Aliment Pharmacol Ther Date: 2010-12-01 Impact factor: 8.171
Authors: Christian Lottrup; Hans Gregersen; Donghua Liao; Lotte Fynne; Jens Brøndum Frøkjær; Klaus Krogh; Julie Regan; Peter Kunwald; Barry P McMahon Journal: J Gastroenterol Date: 2015-05-16 Impact factor: 7.527